translation agency

Business Wire
U.S. Food and Drug Administration Approves New Formulations of Viread(R) for Use by Children Living With HIV

January 18, 2012
Business Wire - January 18, 2012

-- Viread Now Available in an Oral Powder and Three Lower-Strength Tablets -- FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved Viread(R) (tenofovir disoproxil fumarate) in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12. The FDA approved a supplemental New Drug Application (sNDA) for three lower-strength once-daily tablets of Viread in doses of 150 mg, 200 mg and 250 mg for children ages 6-12. The agency also approved a New Drug Application (NDA) for an oral powder formulation of Viread for children ages 2-5. The active ingredient in Viread, tenofovir disoproxil fumarate, is currently the most-prescribed molecule for adults receiving HIV therapy in the United States.